by Suzanne M. Marks, Sundari R. Mase, Sapna Bamrah Morris
Clin Infect Dis (2017) 64 (12): 1670-1677 – Published: 14 March 2017
Evidence-based recommendations for treating persons having presumed latent tuberculosis (LTBI) after contact to infectious multidrug-resistant (MDR) tuberculosis (TB) are lacking because published data consist of small observational studies. Tuberculosis incidence in persons treated for latent MDR -TB infection is unknown. The authors found a reduced risk of TB incidence with treatment for MDR-LTBI, suggesting effectiveness in prevention of progression to MDR-TB, and confirmed cost-effectiveness. However, they found that pyrazinamide-containing MDR-LTBI regimens often resulted in treatment discontinuation due to adverse effects.